Safety and efficacy of switching from dulaglutide to tirzepatide across clinically relevant baseline characteristics in participants with T2D: subgroup analysis of SURPASS-SWITCH.
Switching to a newer diabetes drug from an older one proves safe and effective, offering people another step toward better blood sugar control.
This Phase IV RCT subgroup analysis from SURPASS-SWITCH shows that switching from dulaglutide to tirzepatide is safe and effective across various baseline characteristics in type 2 diabetes. The data supports clinical decision-making for GLP-1 RA treatment intensification.
What the study was
- Study design
- Randomized controlled trial (Phase IV), subgroup analysis
- Population
- Type 2 diabetes patients switching from dulaglutide to tirzepatide
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- BMJ Open Diabetes Research & Care
Why it surfaced
Phase IV RCT subgroup data directly relevant to current prescribing decisions for tirzepatide switch.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.